MEBO International Inc in California of USA is the company for general management and general operating of all the intellectual properties of Dr. Xu and MEBO Group.
“MEBO” is the acronym of Moist Exposed Burn Ointment, the English name of a drug which was approved in 1988 to treat deep burns by regenerating skin organ in situ. The birthday of this drug is also the birthday of MEBO Group. MEBO International Inc is the general IP holding company for the intellectual properties of MEBO Group.
MEBO Group (www.mebo.com), founded by Rongxiang Xu, is an independent scientific group dedicated to the study of in situ human organ regeneration. It is comprised of its own independent organizations including basic regenerative medicine research institutes, clinical research institutes, clinical hospitals, pharmaceutical factories, the club of human regenerative life, etc. Its technology has spread out and benefited people in 73 countries. Its science has benefited the entire world.
From the study to elucidate the mystery and mechanism of in situ skin organ regeneration by the founder, Rongxiang Xu, in 1984, to the announcement of successful demystifying the in situ regeneration of major organs in 2002, 16 years of basic research leads to the establishment of the basic system of Human Body Regenerative Restoration Science, i.e., “Discover and invention of a type of cell with regenerative potential existing in all tissues and organs of the human body, which cell’s regenerative function can be awakened under the nourishment of proper nutritional substance composition optimal for implementing its function, and play the role of stem cells in situ to regenerate new cells to replenish the damaged or defected cells and replace premature senescent cells and diseased cells and so on, eventually restore the normal structure and function of damaged or diseased organs.” In 2001, all research results were packaged together and patent applications were filed for platform technology in USA, China and other countries. In the US nowadays, 15 patents have been issued, and more contents of the patent platform will be submitted successively for substantive review. Nevertheless, the scientific system and route of regenerating damaged organs has been protected by the title of issued patents. In China, it has been protected by 18 issued patents including the patent of Potentially Regenerative Cells (PRCs). The core of the scientific system of In Situ Human Organ Regenerative Restoration is the awakening of congenitally existing Potentially Regenerative Cells in the human body with the in vivo regenerative nutrients. After being awakened and nourished by regenerative nutrients, PRCs play the role of stem cells in situ to restore the normal structure and function of damaged organs under the orchestrating regulation of the human body.
Since 2002, MEBO has been fully devoted to the applied study on in situ human organ regenerative restoration. By the end of 2005, study on organ regenerative restoration in male rats was accomplished with the result demonstrating that middle-aged rats fed with regenerative substances reveal younger organs status when they live to the age of double their normal life span. Since 2006, in addition to the continuous popularization of the skin organ regenerative restoration technology and drug to regenerate human body surface organ damages around the world, MEBO initiated the comprehensive study on human body regenerative nutrition under the support of volunteers who were top governmental officials and terminal cancer patients in China and other countries, which has achieved the effect of in situ human organ regenerative restoration and regenerative rejuvenation. Skin organ regenerative restoration technology for body surface organ damages has been applied as routine treatment in 73 countries. In the US, as early in 1989, former president Senior George Bush proposed to introduce burn skin regeneration technology into USA. Unfortunately, the application of skin organ regeneration technology was delayed in USA due to the lack of FDA regulations on multiple botanical ingredients drug. Today, US government has had legislation on “multiple-ingredient botanical drug products”, and MEBO skin regeneration drug is currently in the stage of preparation for phrase III clinical trial of FDA in the US.
MEBO International Inc (www.mebo-international.com) was founded in California of the US after the patent application had been submitted for the platform technologies of Human Body Regenerative Restoration Science in the US, China and other countries. It is the company for general management and general operating of all the intellectual properties of MEBO Group (including all intellectual properties of the founder, Dr. Rongxiang Xu), in other words, MEBO International Inc is the general IP holding company for the intellectual properties of MEBO Group. Any country around the world looking forward to introducing in situ human organ regeneration science and technology shall contact MEBO International Inc in the US. The mission statement of MEBO International Inc is to benefit the people of all nations around the world with Human Body Regenerative Restoration Science and technologies as soon as possible, in collaboration with the efforts of all countries.
SOURCE: MEBO International